Dr. Kaminski


NAME:

Joseph M Kaminski, M.D.
Dattoli Cancer Center & Brachytherapy Research Institute
2803 Fruitville Road
Sarasota, Florida 34237

TELEPHONE:

(941) 957-1221 (office)

EDUCATION:

Medical Doctorate
Medical College of Georgia
Augusta, GA
1999

Bachelor of Science
With Highest Honors
Georgia Institute of Technology
Atlanta, GA
1994

POSTDOCTORAL TRAINING:

Radiation Oncology Residency
Vanderbilt University Medical Center
Nashville, TN
2005

Nuclear Medicine Residency
Vanderbilt University Medical Center
Nashville, TN
2004

Radiation Oncology Residency
Fox Chase Cancer Center
Philadelphia, PA
2003

Internship
Abington Memorial Hospital
Abington, PA
2000

ACADEMIC HONORS, GRANTS, AWARDS:

Merit Award, NIH/NIAID, 2008

Physicians’ Practice Group Scholarship (Full Tuition plus stipend), 1995-1997
Medical College of Georgia

Outstanding graduate, College of Sciences; 1994
Georgia Institute of Technology

CERTIFICATION & LICENSURE:

Radiation Oncology, American Board of Radiology (#55056)
Florida ME 112967 (exp. date 1/31/2016
Georgia 05109 (exp. date 12/31/16
Ohio 098523 (exp. date 10/16)

PRIOR PROFESSIONAL APPOINTMENTS:

Staff Radiation Oncologist (Associate Professor),
Co-leader of the Neurological Oncology Multidisciplinary Program
Director of the GI, GU, and CNS Radiation Therapy Programs
January 2014-Present
Georgia Regents University
Medical College of Georgia
Augusta, GA
Description: Staff radiation oncologist (IMRT, IGRT, SBRT/SRS, VMAT, etc), full time patient care

Staff Radiation Oncologist, February 2012-January 2014
Mercy Cancer Center
Tiffin, OH
Description: Staff radiation oncologist

Staff Radiation Oncologist, March 2008-January 2012
NCI/NIH
Bethesda, MD
Description: Staff radiation oncologist

Lead Medical Officer (GS15 Step 6, 7/Title 38), December 2008-December 2011
Center for Drug Evaluation and Research and on Detail at the Center for Devices and Radiological Health, August 2010-July 15, 2011
Food and Drug Administration
Silver Spring, MD

Medical Officer (GS14 Step 9), June 2007-December 2008
Office of Product Development,
Radiation Countermeasures and Emergency Preparedness Branch
Division of Allergy, Immunology and Transplantation
NIAID/NIH
Bethesda, MD

Staff Radiation Oncologist (Assistant Professor), May 2004-June 2007
Dept. of Radiology, Radiation Oncology
Georgia Regent’s University (Medical College of Georgia)
Augusta, GA
Description: Adjunct faculty from May 2004-July 2005; Staff radiation oncologist and principal investigator of a laboratory investigating non-viral vectors (responsible for 2 junior faculty and 1 post-doctoral fellow) from August 2005-June 2007.

CONSULTING WORK:

Consultant, 2014-present
Varian Medical Systems
Palo Alto, CA

Consultant, 2009-2011
Professional Disability Associates
Portland, ME
Description: Chart review for disability claims

OTHER PROFESSIONAL ACTIVITIES AND/OR APPOINTMENTS:

Assistant Clinical Professor, 2012
University of Toledo Medical Center
Toledo, OH

 

Assistant Professor of Radiology/Radiological Sciences. January 1, 2010-January 2012
Uniformed Services University of the Health Sciences
F.Edward Hebert School of Medicine
Bethesda, MD
Description: Adjunct faculty appointment from teaching residents. Lectured and gave mock oral boards to the residents

Member, 2005-2007
Intellectual Property Committee
Georgia Health Sciences University (Medical College of Georgia)
Augusta, GA

Faculty, Graduate School
Georgia Health Sciences University (Medical College of Georgia)
Augusta, GA

Member, August 2005-June 2006
Institute of Molecular Medicine and Genetics
Georgia Health Sciences University (Medical College of Georgia)
Augusta, GA

Instructor for Nuclear Medicine Technology Students
Vanderbilt University Medical Center
July 2003-June2004

COMMITTEE/PANEL/WORKSHOPS:

Member, NIH Study Section, Topic 291, RFP N44CO47004-13, Radiation Modulators Special Emphasis Panel, 2014

Member, FDA Subcommittee, American Society for Radiation Oncology (ASTRO), September 2013-present.

Member, Funding Advocacy and Clinical Trials Committee, American Society for Radiation Oncology (ASTRO), September 2013-present.

Member, NIH Study Section, Topic 291, RFP: N44C031014-51, Radioprotector/Mitigator Development to Decrease Normal Tissue Injury During Radiotherapy, 2013.

Member and Cancer Liaison Physician for the cancer program at Mercy Tiffin (American College of Surgeons’ Cancer Program), May 2012-January 2014

Member, NIH Study Section SBIR Phase IIB Bridge awards to accelerate the development of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics toward commercialization (R44), RFA-CA-12-023, 2013.

Member, NIH Study Section, SBIR Topic #258; Innovative Devices to Protect Radiosensitive Organs (Phase II). June 2012.

American Society for Gene and Cell Therapy Symposium Program Planning Participant. September 26-27, 2011.

Member, NIH Study Section, Topic 291: Radioprotector/mitigator to decrease normal tissue injury during radiotherapy, Feb 2011

Co-organizer, FDA: Drug, Device, and Biologic regulatory Issues. Society of Nuclear Medicine 58th Annual Meeting, June 2011.

Co-organizer and Co-moderator: DHHS/ASPR: The Local and Federal Nuclear/Radiobiological Laboratory Network for a Mass Casualty Event. Accepted to Society of Nuclear Medicine 58th Annual Meeting, June 2011.

Member, FDA Study Section, Advancing Regulatory Science through Novel Biomarker Research and Science Based Technologies (U01) July 2011.

Member of the NIH”s Earl Stadtman Search’s Biomedical Engineering/Biophysics/Physics Committee, July 2010.

Co-organizer and Co-moderator, FDA: Clinical and nonclinical regulatory topics. Society of Nuclear Medicine 57th Annual Meeting, June 2010.

Panel Member, Biological Consequences and Health Risks of Low-level Exposure to Ionizing Radiation Workshop. Columbia Chapter of the Health Physics Society. Richland, WA. May 2010.

Member, Technical Evaluation Panel for HHS-BARDA-09-36; Point of Care or High-Throughput Biological Assays for Determining Absorbed Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events. May 2009. Contract amount ~ 40 million each over 5 years.

Co-Moderator, FDA: Update: The Radioactive Drug Research Committee (RDRC) Program and Chemistry Manufacturing and Control (CMC) Regulations, Society of Nuclear Medicine 56th Annual Meeting, June 14, 2009.

Member, NCRP Scientific Committee 1-8 (SC1-18) on the Use of ionizing radiation screening systems for detection of radioactive materials that could represent a threat to homeland security. 2009.

Chair for the Session on Aging and Innate Immunity, Aging and Immunosenescence Workshop, U.S.-Japan Cooperative Medical Science Program, San Francisco, CA, June 18-21, 2008.

Panel Member, Radiation/Nuclear Animal Models for ARS Workshop, Co-sponsored by CBER/CDER/NIAID, Bethesda, MD, September 17-18, 2008.

Panel Member, Stakeholder Workshop of the Security and Continued Use of Cesium-137 Chloride Sources, Bethesda, MD, September 29-30, 2008.

Chair for the Session on Breakdown and Reconstitution of Immune Systems, Radiation Effects Research Foundation-NIAID, Hiroshima, Japan November 27-29, 2007

Interim Co-chair for Mass Casualty Care/Community Planning, Healthcare & Public Health (HPH) Sector Research & Development (R&D) Executive Joint Advisory Working Group (JAWG), DHHS; October-December 2007.

ADMINISTRATIVE PANELS:

Appointed by Dr. Donald Wright (Principle Deputy Assistant Secretary of Health) on behalf of Secretary Leavitt to a DHHS administrative panel to review his decision because a petition was filed by a class of workers from the Rocky Flats Plant in Golden, Colorado, who he determined should not be added to the SEC, March-December 2008 (~100 hours in meetings).

CERTIFICATES:

Project Officer (Contracting Officer’s Technical Representative), National Institutes of Health, Completed on November 2007

FDA-CDER Leadership Institute, Kellogg School of Management, November 1-6, 2009

EDITOR AND EDITORIAL BOARD MEMBER:

Editorial Board Member, Journal of Clinical Radiation Oncology, September 2015-present

Editorial Board Member, International Journal of Low Radiation, July 2010-2014

Co-Editor with Gregory Sempowski, Elizabeth Kovacs, Andrea DiCarlo. Trends in Immunology (Special issue on immunosenescence); July 2009.

AD HOC REVIEWER:

Journal: Molecular Therapy, Southern Medical Journal, J Gene Medicine, BioDrugs, Acta Biochimica Biophysica Sinica, Genome Biology, Proc Natl Acad Sci USA, BMC Biotechnology, Nucleic Acids Research, Theriogenology. Molecular Cancer

Organizations: NCRP, ASPR (including BARDA), NIH, DOD

OTHER USG WORKING GROUPS:

Acute Radiation Syndrome Project Coordinating Team, Biomedical Advanced Research and Development Authority (BARDA); 2007

Blood and Tissue (BARDA); 2008

Prochymal Medical Radiation Countermeasure Integrated Product Team (DOD); 2008

Trans-NIH Pharmacogenomics Coordination Group; 2008

Radiological/Nuclear Integrated Program Team (BARDA); 2008-2009

Trans-NIH Gene Therapy Working Group; 2008

Task Group Member/Participant. Radiation Laboratory Network. DHHS/ASPR , 2010-2011

PUBLICATIONS IN NON REFEREED JOURNALS:

(1) Summers JB, Kaminski J. Defending our coverage of the Anderson case. The Scientist. August 26, 2004. on-line.

 

(2) Summers JB, Kaminski J. Incomplete bibliographies. The Scientist. 2005; 19:8.

(3) Summers JB, Kaminski J. Revisited: Sued by your patients victim. Medical Economics. July 9, 2004.

 

(4) Summers JB, Kaminski J. Are you your patients keeper? Medical Economics. 2003; 80:.

 

(5) Summers JB, Kaminski J. Is it first-or not? The Scientist; 2004; 18:11.

 

(6) Maidment B, Benjamin J, Cassatt D, DiCarlo A, Kaminski J, et al. Radiation/nuclear medical countermeasures development program. 12th Congress of the Proceedings of the International Radiation Protection Association, Paper 0831, 2008.

ABSTRACTS/PRESENTATIONS:

(1) Kaminski JM. Targeted Integration. Sequenom, Inc. San Diego, CA; Invited (12/02).

 

(2) Kaminski JM. Targeted Integration. Imperial College. London, England; Invited (5/03).

 

(3) Kaminski JM, et al. A platform technology for applications in cancer therapy: site-specific transposon integration. Gordon Conference Jan. 2005 for Radiation Oncology (Ventura, CA).

 

(4) Kaminski JM, et al. Site-Specific Integration and Its Role for Cancer Gene Therapy. 96th AACR Meeting. Abst. 3347, pg. 243, April 2005.

 

(5) Kaminski JM, et al. Site-specific transposon integration. Molecular Therapy 11(Suppl. 11):S424; 2005. Oral Presentation.

 

(6) DiChristina TJ, Kaminski JM, et al. Detection of Fe3+ Bacteria in the Water Column and Sediments of the Gulf of Maine. Abstracts of the 94th General Meeting of ASM, 422, 1994.

 

(7) Kaminski JM, et al. The relationship between prostate volume, PSA nadir, and biochemical control. Int J Radiat Oncol Biol Phys 51: (suppl. 1) abs. 2126, 2001.

 

(8) Kaminski JM, et al. Radiosensitization is not increased with the addition of adenoviral-E2F when combined with adenoviral-p53 mediated gene transfer. Radiation Research Society 49th Annual Meeting abs. P21-225, 2002.

 

(9) Kaminski JM, et al. Three dimensional conformal radiation as adjuvant and salvage therapy after prostatectomy. American Radium Society 84th Annual Meeting P26, 38, 2002.

 

(10) Kaminski JM, et al. Extended neoadjuvant androgen ablation and radiation in prostate cancer. The optimal sequence? Oral presentation, PSOH, 1, 2002.

 

(11) Kaminski JM, et al. The effect of sequencing of androgen ablation and radiation on prostate cancer growth. Int J Radiat Oncol Biol Phys 54: 1055. Poster Discussion, ASTRO 2002.

 

(12) Kaminski JM, et al. Unraveling the abscopal effect. VUMC 22nd Annual Research Forum. Poster Presentation, Basic Science Research Abstracts 2004; 16.

 

(13) Kaminski JM, et al. Recombinant peptides targeted to the radiation-inducible response in tumor microvasculature. Int J Radiat Oncol Biol Phys 60; S195; ASTRO 2004 for Oral Presentation.

 

(14) Kaminski J, et al. Evanescent wave biosensors: incorporation of a third moiety. International Conference of Biological Physics Abstract A03-124. 2004; 66.

 

(15) Kim DW, Fu A, Niermann K, Kaminski J, et al. Int J Radiat Oncol Biol Phys 60; S175; ASTRO 2004 for Oral Presentation. (Speaker Kim, DW)

 

(16) Kaminski JM. Targeted Therapies for High Grade Gliomas. Poole Society, Augusta, GA; Invited (3/06).

 

(17) Moisyadi S, Suganuma R, Morozumi K, Pelczar P, Kaminski JM, et al. New transgenesis and transfection with Transposase enzymes. International Symposium: Cell Signaling in Gametic Activation- from Basic Research to ART. Tokyo Woman’s Medical University. 11/15/06, abst. Oral Presentation. (Speaker: Moisyadi, S)

 

(18) Kaminski JM. Targeted Integration, Lentigen Corporation, Baltimore, MD (1/07). Invited.

 

(19) Suganuma R, Morozumi K, Pelczar P, Kaminski JM, et al. New Transgenesis and Transfection with Transposase enzymes. Transgenic Research (2006) 15:775. 7th Transgenic Technology Meeting. February 12th-14th, 2007. Institute of Molecular Biosciences, University of Queensland, St. Lucia, Brisbane, Australia. Oral Presentation. (Speaker: Moisyadi, S)

 

(20) Kolhe R, Kaminski J, et al. Extended-release of Flt intraceptors in the cornea inhibit injury- induced corneal angiogenesis. 2007 FASEB Conference. Late Breaking Abstract. pg. LB86, abstract. LB404.

 

(21) Kolhe R, Kaminski J, et al. PiggyBac Enhanced Transgenesis and Transfection. 2007 FASEB Conference. Late Breaking Abstract. pg. LB86, abstract LB403.

 

(22) Sarvida M, Xie L, Burnight E, McCray PB, Kaminski JM. Phenotypic correction and long-term expression of factor VIII in hemophilia mice by non-viral gene transfer using the piggybac transposon system. Oral presentation (Platform Session) at American Society of Pediatric Hematology/Oncology, May 2008. (Speaker: Sarvida, M)

 

(23) Kawasumi M, Morozumi K, Pelczar P, Kaminski, JM, et al. Transgenesis with transposase enzymes. The Sixth annual International Conference on Transposition and Animal Biotechnology. June 19-21, 2008. Berlin, Germany.

 

(24) Bader JL, Chang F, Nemhauser J, Coleman N, Kaminski JM. Radiation Event Medical Management: Teaching biodosimetry to responders. Hanover, NH (Dartmouth), Oral Poster Presentation September 2008 (Speaker Kaminski, JM).

 

(25) Ramakrishnan N, Dicarlo-Cohen A, Kaminski J, et al. CMCR program: overview and progress. 54th Annual Meeting of the Radiation Research Society. Boston, MA, September 2008. Oral Presentation (Speaker: Ramakrishnan N).

 

(26) Kaminski JM. Active Transgene Integration: Transgenesis and Gene Therapy, Trans NIH Gene Therapy Meeting, Bethesda, MD; Invited (10/08).

 

(27) Maidment B, Kaminski JM, Hatchett R. R&D program overview at the NIAID/NIH. The 12th Coordination and Planning Meeting of the WHO REMPAN Collaborating Centers and Liaison Institutions, October 15-17. Buenos-Aires, Argentina. Oral Presentation. Invited (Speaker: Bert Maidment, Ph.D.).

 

(28) Kaminski JM. Mo-99/Tc-99m Shortage. Society of Nuclear Medicine Annual Meeting June 2009. Oral Presentation. Invited.

 

(29) Staber JM, Burnight E, Xie L, Kaminski J, et al.Nonviral Gene Transfer to Hepatocytes Utilizing the Piggybac Transposon System: An Approach towards Hemophilia A Correction and Long Term Expression of Factor VIII. American Society of Pediatric Hematology/Oncology, April 2009.

 

(30) Manuri PR, Maiti SN, Singh H, Mi T, Olivares S, Dawson MJ, Huls H, Lee DA, Rao, PH, Kaminski JM, et al. PiggyBac, an efficient method for genetic modification of T cells with second generation CD19-specific chimeric antigen receptor (CAR) for treatment of B-lineage malignancies. ASGT May 2009.

 

(31) Burnight ER, Staber J, Sarvida M, Xie L, Kaminski JM, et al. Gene transfer to murine liver using a piggyBac transposon system. Oral Presentation. ASGT May 2009. (Speaker: Burnight, ER?)

 

(32) Kaminski JM. Tc-99m Shortage. Society of Nuclear Medicine 56th Annual Meeting, June 14, 2009. Oral Presentation Invited.

 

(33) Urschitz J, Stoytchev I, Owens J, Dee JA, Yamashiro H, Morozumi K, Pelczar P, Kawasumi M, Kaminski JM, et al. Transgenesis with transposase enzymes. VI Transgenic Animal Research Conference of U.C. Davies.  August 17-21, 2009 at the Granlibakken Conference Center, Tahoe City, Lake Tahoe, California, USA.

 

(34) Kaminski JM. Piggybac Gene Therapy and Transgenesis. Sun Yat-Sen University. Guangzhou, China, October 12, 2009. Invited.

 

(35) Urschitz J, Walton C, Owens J, Stoytchev I, Pelczar P, Kaminski JM, et al. Helper independent piggyback vectors for gene therapy. Cold Springs Harbor: In vivo barriers to gene therapy. November 2009.

 

(36) Kaminski, JM. Non-radiation causes of carcinogenesis and other health effects in the atomic bomb survivors. Biological Consequences and Health Risks of Low-level Exposure to Ionizing Radiation Workshop. Columbia Chapter of the Health Physics Society. Richland, WA, May 2010. Invited Panel Member. Abstract Health Phys 2011; 100(3):309.

 

(37) Kaminski, JM and Choi, S*. Medical Imaging Initiative. Oral Presentation. SNM Annual Meeting 2011.

 

(38) Al-Basheer A, ….Kaminski, JM, et al. Evaluation of Integral Dose in Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy for Head and Neck Cancer Patient. Oral Presentation AAPM (Austin, TX) July 20-24, 2014

 

(39) Huang, J, Kaminski JM, et al. Low Baseline Lymphocyte count may predict poorer overall survival in patients with head and neck cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 90:15 abs. 2920, 2014.

 

(40) A. Al-Basheer, J. Huang, J. Kaminski, B. Dasher, J. Howington, J. Stewart, D. Martin, J. Jin, F. P. Kong Correlation Of Integral Does, White Blood Cell Counts, And Radiotherapy Techniques For Head And Neck Cancer Patients Under Radiotherapy. ASTRO 56th annual meeting. San Francisco, CA. September 14-16, 2014

 

(41) J. Zhao, A. Al-Basheer, B. Dasher, M. Frank, Z. Hao, J. Howington, J. Howington, J. Kaminski, J. Stewart, P. Ye, F. Kong. Peripheral White Blood Cell Counts May be a Significant Factor for Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Radiotherapy. 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago Il October 30- November 1st 2014

 

(42) J Zhao, A Al-Basheer, B Dasher, F Mott, Z Hao, J Howington, J‎ Howington, J‎ Kaminski, P Ye, F Kong Peripheral White Blood Cell Counts May be a Significant Factor for Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Radiotherapy. ASCO 50th annual meeting, Chicago IL May 30- June 3rd 2014

 

(43) Zaenger, et al, Kaminski, JM. From benign CNS SRS therapy for pain to SRS treatments for facetogenic pain: extrapolating safety. American Association of Neurological Surgeons (AANS) 83rd Annual Meeting in Washington DC, 2015.

 

(44) Zaenger D, Rabatic BM, Kaminski JM, et al. Long-term functional and oncologic outcomes of ethesioneuroblastoma.(P084). American Radium Society 97th Annual Meeting, Oncology: 29 (Suppl 1):63, 2015.

 

(45) Zaenger D, et al, Kaminski JM. Clinical Outcomes of Gamma Knife SRS for painful trigeminal neuropathy. (P041). American Radium Society 97th Annual Meeting Oncology: 29 (Suppl 1):44,2015.

 

(46) Rabatic BM, Zaenger D, Kaminski JM, et al. Oncologic and functional outcomes of salivary gland tumors (SGTs) with pathologically proven perineural invasion (PNI). (P085) American Radium Society 97th Annual Meeting, Oncology: 29 (Suppl 1):64 2015.

NIH PUBLICATIONS: RFA’S AND RFP’S:

(1) BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Cutaneous Injury: Project Bioshield (RC1). (RFA-AI-07-037). http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-07-040.html. National Institute of Allergy and Infectious Diseases; December 2007

(2) BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Pulmonary Injury: Project Bioshield (RC1). (RFA-NIH-NIAID-AI-07-040). http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-07-037.html. National Institute of Allergy and Infectious Diseases; December 2007

(3) Studies of Immunosenescence and Other Late Effects of Acute Ionizing Radiation Exposure in Atomic Bomb Survivors. https://www.fbo.gov/index?s=opportunity&mode=form&id=d7d84c28d90028966a176a438b729287&tab=core&tabmode=list

USG WHITE PAPERS:

(1) Neupogen® in the Strategic National Stockpile to Address Neutropenia Associated with Acute Radiation Syndrome Issues Regarding Potential Use in an Emergency: A White Paper for the Enterprise Executive Committee; 2007

(2) Blood and tissue requirements following detonation of a 10 kT improvised nuclear device. Blood and Tissue Working Group, White Paper for the Enterprise Executive Committee; 2009.

PUBLISHED POSTERS:

The immune system in the old. Trends in Immunology. July 2008.

BOOK CHAPTERS:

(1) Wu C-Y, Kommineni J. Maragathavally, Coates CJ, and Kaminski JM. Steps Towards Targeted Insertional Mutagenesis with Class II Transposable Elements. Chromosomal Mutagenesis. Methods in Molecular Biology #435, eds. Gregory D. Davis and Kevin J. Kayser. (The Humana Press, Totowa, NJ), 2008.
(2) Hatchett RJ, Kaminski JM, Goans RE, Nuclear and radiological events. Disaster Medicine, Comprehensive Principles and Practices. eds. Kristi Koenig and Carl H. Schultz. (Cambridge University Press, New York, NY), 2009, 477-510.

COMMENTARY REPORT:

(1) Commentary on active detection technology. Report of SC1-18. National Council for Radiation Protection and Measurements.

PATENTS:

(1) Kaminski JM. Transposon-based vectors and methods of nucleic acid integration. Australia 2003268022 and Europe 2003748973

PUBLICATIONS IN PEER-REVIEWED JOURNALS:

Original Clinical or Basic Research

(1) Kaminski JM, et al. The relationship between prostate volume, PSA nadir, and biochemical control. Int J Radiat Oncol Biol Phys 2002; 52:888-892.

 

(2) Kaminski JM, et al. The effect of sequencing androgen ablation and radiation on prostate cancer growth. Int J Radiat Oncol Biol Phys. 2003; 57:24-8.

 

(3) Wilson MH, Kaminski JM, et al. Functional zinc finger/Sleeping Beauty transposase chimeras exhibit loss of overproduction inhibition. FEBS Lett. 2005; 579:6205-9.
(4) Maragathavally KJ, Kaminski J, et al. Gal4-Mos1 and Gal4-piggyBac chimeric transposases results in site-specific integration. FASEB J. 2006; 20:1880-2.
(5) Wu C-Y, Meir Y-J, Coates CJ, Handler AM, Pelczar P, Moisyadi S, Kaminski JM. piggyBac is a Flexible and Highly Active Transposon as Compared to Sleeping Beauty, Tol2, and Mos1 in Mammalian Cells. Proc Natl Acad Sci U S A. 2006; 103:15008-13.
(6) Yu K, Zhuang J, Kaminski JM, et al. CXCR4 Down-Regulation by Small Interfering RNA Inhibits Invasion and Tubule Formation of Human Retinal Microvascular Endothelial Cells. Biochem Biophys Res Commun. 2007; 358:990-6.
(7) Yu K , Ge J, Li F, Liu X, Ma P, Kaminski J*, et al. TSP1 Secreted by the Bone Marrow Stromal Cells Contribute to Retinal Ganglion Cell Neurite Outgrowth and Survival. PLOS One 2008; 3(6):e2470. *Co-corresponding author
(8) Zhuang J, Li F, Liu X, Liu Z, Lin J, Ge Y, Kaminski JM, Summers JB, Wang Z, Ge J, Yu K. Lithium Chloride Protects Retinal Neurocytes from Nutrient Deprivation by Promoting DNA Non-homologous End-joining. Biochem Biophys Res Commun. 2009; 380:650-4.
(9) Raja Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for treatment of B-lineage malignancies. Hum Gene Ther 2010; 21:427-37.
(10) Zhuang J, Ye Y, Liu X, Li F, Pan X, Chen Z, Luo H, Ge Y, Ge J, Kaminski J, Yu K.DNA methylation in retinal neurocytes contributes to up-regulation of DNA repair protein, Ku-80. Neuroreport. 2010; 21:282-6.
(11) Urschitz J, Kawasumi M, Owens J, Morozumi K, Yamashiro H, Stoytchev I, Marh J, Dee JA, Kawamoto K, Coates CJ, Kaminski JM, et al. Helper-independent piggyBac plasmids for gene delivery approaches: Strategies for avoiding potential genotoxic effects. Proc Natl Acad Sci U S A 2010 Apr 19. [Epub ahead of print]
(12) Xue-ke P, Zhao C, Si-jia T, Kaminski JM, et al. Expression of exogenous Rb gene mediated by piggybac transposon in retinoblastoma cells. Chinese Journal of Tissue Engineering Research 2012; 16:3755-3758.
(13) Jin JY, Zhao B, Kaminski JM, et al. Radiother Oncol. 2015 Aug 12. pii: S0167-8140(15)00408-9. doi: 10.1016/j.radonc.2015.07.047.
(14) Jin JY, Huang Y, Brown SL, Movsas B, Kaminski J, et al. Radiation dose fractionation effects in spinal cord: comparison of animal and human data. J Rad Oncol. 14 August 2015. 10.1007/s13566-015-0212-9.
(15) DiCarlo AL, Kaminski JM, et al. Role of thrombocytopenia in radiation-induced mortality and review of therapeutic approaches targeting platelet regeneration after radiation exposure. J Rad Oncol. 1 July 2015. 10.1007/s13566-015-0201-z

 

 

Hypothesis

(16) Kaminski JM, et al. The design of a non-viral vector for site-selective, efficient integration into the human genome. FASEB Journal 2002; 16:1242-1247.

 

Reviews

(17) Kaminski JM, et al. Defining a future role for radiogenic therapy. Cancer Treatment Reviews 2001; 27:289-294.
(18) Kaminski JM, et al. Prostate cancer gene therapy and the role of radiation. Cancer Treatment Reviews 2002; 28:49-64.
(19) Kaminski JM, et al. Immunotherapy and prostate cancer. Cancer Treatment Reviews 2003; 29:199-209.
(20) Kaminski JM, et al. Radiation therapy in the treatment of airway tumors other than small cell carcinoma and non-small cell carcinoma. Chest Surgery Clinics of North America 2003; 13:149-167.
(21) Kaminski J, et al. The controversial abscopal effect. Cancer Treatment Reviews. 2005;31:159-72.
(22) Kolb AF, Coates CJ, Kaminski JM, et al. Site-directed genome modification: nucleic acid and protein modules for targeted integration and gene correction. Trends in Biotechnology. 2005; 23:399-406.
(23) Coates CJ, Kaminski JM, et al. Site-directed genome modification: derivatives of DNA-modifying enzymes as targeting tools. Trends in Biotechnology. 2005; 23:407-419.
(24) Shinohara ET, Kaminski JM*, et al. Active Integration: New Strategies for Transgenesis. Transgenic Research. 2007;16:333-9. *Co-corresponding author
(25) Jaboin JJ, Shinohara ET, Moretti L, Yang ES, Kaminski JM, et al. The Role of mTOR Inhibition in Augmenting Radiation Induced Autophagy. Technol Cancer Res Treat. 2007; 6:433-48.
(26) Moisyadi S, Kaminski JM*, Yanagimachi R. Use of ICSI to generate transgenic animals. Invited review for Comparative Immunology, Microbiology, and Infectious Diseases. 2008 Aug 6. [Epub ahead of print] *Co-first author
(27) DiCarlo AL, Hatchett RJ, Kaminski JM, et al. MEETING REPORT: Medical Countermeasures for Radiation Combined Injury: Radiation with Burn, Blast, Trauma and/or Sepsis. Radiat Res. 2008; 169(6):712-21
(28) Tubiana M, Feinendegen L, Yang C, Kaminski JM. The linear no-threshold relationship is inconsistent with radiobiologic and experimental data. Radiology. 2009; 251:13-22..
(29) Cassatt D, Kaminski JM, et al. Medical Countermeasures against Nuclear Threats: Radionuclide Decorporation Agents. Radiat Res 2008; 170:540-548.
(30) Grace MB, Moyer BR, Prasher J, Cliffer KD, Ramakrishnan N, Kaminski J, Coleman CN, Manning RG, Maidment BW, Hatchett R. Rapid radiation dose assessment for radiological public health emergencies: roles of NIAID and BARDA. Health Physics. 2010;98:172-8.
(31) Hafer N, Cassatt D, Dicarlo A, Ramakrishnan N, Kaminski J, Norman MK, Maidment B, Hatchett R. NIAID/NIH Radiation/Nuclear Medical Countermeasures Product Research and Development Program. Health Phys. 2010; 98:903-5.
(32) Mettler FA, Brenner D, Coleman N, Kaminski JM, Kennedy AR, Wagner LK. Can radiation risks to patients be reduced without reducing radiation exposure? The status of chemical radioprotectants. Am J Roentgenol 2011; 196:616-8.

Case Reports

(33) Kaminski JM, et al. Intracranial fibrosarcoma arising five years after chemotherapy alone for glioblastoma multiforme in a child. Pediatr Neurosurg 2000; 33: 257-260.
(34) Kaminski JM, et al. Metastatic meningioma to the lung with multiple pleural metastasis. American Journal of Clinical Oncology 2001; 24:579-582.
(35) Andrews SF, Kaminski JM, et al. Delayed reaction. Cortlandt Forum 2002; 15:37-39.
(36) Kaminski CY, Kaminski JM, et al. PET and Intussuception, Where CT Failed. Clin Nucl Med 2003; 28:60-61.
(37) Summers JB, Kaminski J. Two cases of epidural abscesses in cirrhotic patients. Southern Medical Journal. 2003; 96:943.
(38) Summers JB, Kaminski J. Urinary bladder pseudomass as a postoperative US finding. Radiology 2003; 229:291.
(39) Kaminski, JM et al. Small cell carcinoma of the vagina. Gyn Oncol 2003; 88:451-455.
(40) Summers B, Kaminski J, et al. Splenic rupture occurring as a complication of subacute bacterial endocarditis. New Zealand Medical Journal 2003; 116:1-3.
(41) Kaminski JM, et al. Delayed reaction raises concern. Clinical Advisor. March 2004; 88, 92.
(42) Khothsymuong R, Kaminski J. Gallbladder Hydrops. Journal of Diagnostic Medical Sonography 2004; 20:256-259.
(43) Summers JB, Kaminski J. Another case of testicle duplication with contralateral agenesis. South Med J 2005;98:126-7

 

Editorials or Correspondences

(44) Summers JB and Kaminski JM. Nutrition, physical activity, and obesity. Lancet 2002; 360:1249.
(45) Summers JB and Kaminski JM. Citation Etiquette in biomedical publications: false claim of “first reported case”. Comp. Med. 2002; 52:395.
(46) Reilly J, Summers JB, Kaminski JM. Editorial: brachytherapy for the prevention of renal artery in-stent restenosis. Southern Medical Journal. 2003; 96:1094-1095.
(47) Summers JB and Kaminski JM. Complications of low-molecular weight heparins. Southern Medical Journal 2003; 95:1456-1457.
(48) Summers JB, Kaminski J. Old letters new rules. Lancet 2003; 361:705-706. ]
(49) Kaminski J, Summers JB. Delivering zinc fingers. Nature Biotech 2003; 21:492-3.
(50) Summers JB, Kaminski J. Publishing ethics-duplication indiscretion. Ann Pharmacother 2003; 37:749.
(51) Summers JB, Kaminski J. Larval Therapy for Pressure Ulcers. JAMA.2003; 289:2210.

 

 

(52) Summers JB, Kaminski J. To question or not to question? Birth. 2003; 20:141.
(53) Summers JB, Kaminski J. Perceptual puzzle. Acad Rad. 2003; 10:803.
(54) Summers JB, Kaminski J. Errors in surgery Can J Surg. 2003; 46:307.
(55) Summers JB, Kaminski J. Maggot debridement therapy (MDT) for burn wounds. Burns 2003; 29: 501-502.
(56) Summers JB, Kaminski J. Letter to the editor. Comp Med 2003; 53:243.
(57) Summers JB, Kaminski J. Restricted weekend services result in delays in discharges from hospital. Clinical Cardiology 2003; 26:A20.
(58) Summers JB, Kaminski J. Making the most of maggots. Nursing 2003; 33: 8-9.
(59) Summers JM, Kaminski J. Maggot therapy for diabetic wounds. American Family Physician. 2003; 68:2327, 2330.
(60) Summers JB, Kaminski J. Is duct tape occlusion therapy an effective treatment of warts? American Family Physician 2003; 1912.
(61) Summers JB, Kaminski J. Foreign bodies. Radiographics. 2003; 23:1701.
(62) Summers JB, Kaminski J, et al. Disciplinary actions by North Carolina Medical Board. AJR 2003; 181:1716.
(63) Summers JB, Kaminski J. Editorial. Ear, Nose, and Throat Journal. 2004;83:303.
(64) Summer JB, Kaminski J. Letter to the editor. Applied Radiology. 2004; 11:10.
(65) Summers JB, Kaminski J. Maggot debridement therapy for diabetic foot ulcer. Resident and Staff Physician 2004; 50:6.
(66) Summers JB, Kaminski J. Letter to the editor. Cancer Treatment Reviews. 2004; 30:213.
(67) Summers JB, Kaminski J. Acronym addiction. Texas Heart Inst J 2004; 31:108-109.
(68) Summers JB, Kaminski J. Inadequate staple removal a concern for burn specialists and radiologists.
Burns. 2004;30:502.
(69) Summers JB, Kaminski J. More on writing good case reports. J Orthop Sports Phys Ther. 2004;34(7):410
(70) Summers JB, Kaminski J. Reading around the subject. Physiother Res Int. 2004;9:108-9.]
(71) Summers JB, Kaminski J. Erroneous claims of priority in publications. Southern Medical Journal 2004; 97:917.
(72) Summers JB, Kaminski J. Reporting instruction for radiology residents. Acad Radiol. 2004;11:1197.
(73) Summers JB, Kaminski JM. False firstedness: The dilemma of priority claims in biomedical publications. J Am Acad Dermatol. 2005;52:735-6.
(74) Summers JB, Kaminski J. Comments about orbital blowout fractures. Resident & Staff Physician 2005; 51(11):3.
(75) Dicarlo AL, Fuldner R, Kaminski J, Hodes R. Aging in the context of immunological architecture, function and disease outcomes. Trends Immunol 2009; 30(7):293-4.


'

Call 1-877-DATTOLI or Send Us a Message Now